

### NRG Oncology Presentation Schedule

Oral, Quick Pitch Oral, Poster, and Educational Presentations

SEPTEMBER 27-OCTOBER 1, 2025

Disease Site & Study #	Saturday, September 27, 2025	Time/Location
Disease Site & Study #	Sunday, September 28, 2025	Time/Location
Prostate  NRG-GU006 BALANCE trial	<b>Title:</b> <i>A Double-Blinded Placebo-Controlled Biomarker Stratified Randomized Trial of Apalutamide (APA) and Radiotherapy for Recurrent Prostate Cancer (NRG GU006, BALANCE trial).</i> <b>Presenter:</b> Daniel Spratt, MD <b>Session Number:</b> CT 01	<b>Location:</b> San Francisco Ballroom <b>Session:</b> Clinical Trials <b>Time:</b> 1:00pm - 1:10pm PT <b>Duration:</b> 10 minutes <b>Oral Presentation</b>
Prostate  NRG-RT0G 0924	<b>Title:</b> <i>Androgen Deprivation Therapy (ADT) and High Dose Definitive Radiotherapy (RT) +/- Whole Pelvic RT in Patients with Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: Early Results of a Phase III Randomized Controlled Trial.</i> <b>Presenter:</b> Mack Roach, MD <b>Session Number:</b> CT 01	<b>Location:</b> San Francisco Ballroom <b>Session:</b> Clinical Trials <b>Time:</b> 1:20pm - 1:30pm PT <b>Duration:</b> 10 minutes <b>Oral Presentation</b>
Cervix  NRG-GOG-9929	<b>Title:</b> <i>Tracking Changes in B Cell Antibodies in Cervical Cancer Patients Treated with Chemoradiation and Immunotherapy on GOG 9929.</i> <b>Abstract #:</b> 124 <b>Presenter:</b> Sangwoo Kim, MD <b>Session Number:</b> SS 04 - GYN 1	<b>Location:</b> Room 160 <b>Session:</b> Molecular and Precision Medicine for gynecologic cancers in diverse resource settings <b>Time:</b> 2:51pm – 2:58pm PT <b>Duration:</b> 10 minutes <b>ORAL Presentation</b>
Prostrate  NRG-CC007CD	<b>Title:</b> <i>Impact of Intensified Survivorship Care Planning on Cardiovascular Care in Prostate Cancer Survivors: Primary Results of NRG-CC007CD.</i> <b>Abstract #:</b> 158 <b>Presenter:</b> Ronald Chen, MD <b>Session Number:</b> SS 10 - Patient Reported Outcomes/QoL/Survivorship 1	<b>Location:</b> Room 314 <b>Session:</b> PRO/QOL/Survivorship: Fixing What's Broken and Reaching for the Sky <b>Time:</b> 4:45pm – 4:55pm PT <b>Duration:</b> 10 minutes <b>ORAL Presentation</b>
Lung  NRG-RT0G 1308 NRG-RT0G 0617	<b>Title:</b> <i>Sociodemographic Factors Associated with Proton Therapy Accessibility in NRG Oncology Trials of Locally Advanced NSCLC.</i> <b>Poster #:</b> 2391 <b>Presenter:</b> Bryan Johnson, MD <b>Session Number:</b> PQA 02	<b>Location:</b> Hall F <b>Session:</b> Lung Cancer/Thoracic Malignancies, Patient Reported Outcomes/QoL/Survivorship, Pediatric Cancer <b>Time:</b> 4:45pm – 6:00pm PT <b>POSTER</b>

GU-Prostate NRG-RTOG 0848	<b>Title:</b> <i>Is patient-reported baseline fatigue associated with overall survival among patients with resected head of the pancreas adenocarcinoma on NRG Oncology/RTOG 0848?</i> <b>Abstract #:</b> 162 <b>Presenter:</b> Lisa A Kachnic, MD <b>Session Number:</b> SS 10	<b>Location:</b> Room 314 <b>Session:</b> Patient Reported Outcomes/QoL/Survivorship 1: PRO/QOL/Survivorship: Fixing What's Broken and Reaching for the Sky <b>Time:</b> 5:25pm - 5:35pm PT <b>Duration:</b> 10 minutes <b>ORAL Presentation</b>
<b>Disease Site &amp; Study #</b>	<b>Monday, September 29, 2025</b>	<b>Time/Location</b>
Head & Neck  NRG-HN002 NRG-RTOG 1016 NRG-RTOG 0522 NRG-RTOG 0234 NRG-RTOG 0129 NRG-RTOG 9501	<b>Title:</b> <i>Development and validation of a digital pathology-based, multimodal artificial intelligence (MMAI) biomarker in patients with head and neck cancer treated with definitive radiation Therapy.</i> <b>Abstract #:</b> 177 <b>Presenter:</b> Steven Chinn, MD <b>Session Number:</b> SS 13 - DHI 1	<b>Location:</b> Room 20/21 <b>Session:</b> The Digital Revolution in Radiation Oncology: AI Models for Enhanced Patient Care <b>Time:</b> 8:00am – 8:10am PT <b>Duration:</b> 10 minutes <b>ORAL Presentation</b>
Prostate  NRG-GU005	<b>Title:</b> <i>Quality of life results from NRG-GU005: a Phase III trial of SBRT vs. Hypofractionated IMRT for localized intermediate risk prostate cancer.</i> <b>Abstract #:</b> 193 <b>Presenter:</b> James Yu, MD <b>Session Number:</b> SS 16 - GU 4	<b>Location:</b> Room 156/158 <b>Session:</b> Quality of Life Outcomes after Prostate Radiotherapy <b>Time:</b> 10:45 – 10:55am PT <b>Duration:</b> 10 minutes <b>ORAL Presentation</b>
Prostate  NRG-GU005	<b>Title:</b> <i>Primary results from NRG-GU005: a phase III trial of SBRT vs. hypofractionated IMRT for localized intermediate risk prostate cancer.</i> <b>Abstract #:</b> 1 <b>Presenter:</b> Rodney Ellis, MD <b>Session Number:</b> PL 01	<b>Location:</b> San Francisco Ballroom <b>Session:</b> Plenary <b>Time:</b> 1:50pm – 1:00pm PT <b>Duration:</b> 10 minutes <b>PLENARY</b>
Breast  NRG-BR007	<b>Title:</b> <i>Feasibility study of AI-assisted radiation therapy contour QA for a breast cancer multi-center clinical trial.</i> <b>Poster #:</b> 2938 <b>Presenter:</b> Huaizhi (Jane) Geng, PhD <b>Session Number:</b> PQA 05	<b>Location:</b> Hall F <b>Session:</b> Breast Cancer, Health Services Research, International/Global Oncology <b>Time:</b> 3:00pm - 4:00pm PT <b>POSTER</b>
N/A	<b>Title:</b> <i>Implementing advanced total body irradiation (TBI) techniques into clinical trials: an NRG hematologic malignancies working group survey.</i> <b>Poster #:</b> 3649 <b>Presenter:</b> Nataliya Kovalchuk, PhD <b>Session Number:</b> PQA 09	<b>Location:</b> Hall F <b>Session:</b> Hematologic Malignancies, Digital Health Innovation and Informatics <b>Time:</b> 4:00pm – 5:00pm PT <b>POSTER</b>
<b>Disease Site &amp; Study #</b>	<b>Tuesday, September 30, 2025</b>	<b>Time/Location</b>
Breast  NRG-NSABP B-24 NRG-NSABP B-35 NRG-NSABP B-43	<b>Title:</b> <i>Utilization of a lumpectomy bed boost after whole breast radiotherapy does not improve ipsilateral breast tumor recurrence risk in patients with ductal carcinoma in-situ treated on three NSABP trials.</i> <b>Abstract #:</b> 279 <b>Presenter:</b> Atif Khan, MD <b>Session Number:</b> SS 31 - Breast Cancer 3	<b>Location:</b> Room 24 <b>Session:</b> Refining Radiation in Early-Stage Breast Cancer: Personalization, Precision, and De-escalation <b>Time:</b> 8:00am - 8:10am PT <b>Duration:</b> 10 minutes <b>ORAL Presentation</b>

Lung  NRG-RTOG 0617 NRG-RTOG 1106	<b>Title:</b> <i>Adaptive vs. non-adaptive radiation dose escalation in locally advanced non-small cell lung cancer (LA-NSCLC): indirect comparison of NRG-RTOG 0617 and 1106 individual patient data.</i> <b>Abstract #:</b> 1048 <b>Presenter:</b> Joseph Miccio, MD <b>Session Number:</b> QP 09 - Lung 4	<b>Location:</b> Room 155/157 <b>Session:</b> Lung Cancer Quick Pitches <b>Time:</b> 8:05am - 8:10am PT <b>Duration:</b> 5 minutes <b>Quick Pitch ORAL Presentation</b>
Brain  NRG-RTOG 0825 WF1801	<b>Title:</b> <i>WF-1801: cognitive outcomes of a single arm pilot study of ramipril for prevention of radiation-induced cognitive decline in glioblastoma patients receiving chemoradiotherapy.</i> <b>Abstract #:</b> 285 <b>Presenter:</b> Amanda Goetz, MD <b>Session Number:</b> SS 32 - CNS 2	<b>Location:</b> Room 310-312 <b>Session:</b> Gliomas: Survivorship and Clinical Trials <b>Time:</b> 8:10am - 8:20am PT <b>Duration:</b> 10 minutes <b>ORAL Presentation</b>
Lung  NRG-LU005	<b>Title:</b> <i>Comprehensive patient reported outcomes (PROs) from NRG LU005: a randomized trial of chemoradiation (CRT) +/- Atezolizumab in limited-stage small cell lung cancer (LS-SCLC).</i> <b>Abstract #:</b> LBA 08 <b>Presenter:</b> Benjamin Movsas, MD <b>Session Number:</b> LBA 01	<b>Location:</b> Room 22/23 <b>Session:</b> Late Breaking Abstracts <b>Time:</b> 2:30pm – 2:40pm PT <b>Duration:</b> 10 minutes <b>ORAL Presentation</b>
Head & Neck  NRG-HN005	<b>Title:</b> <i>AI-Assisted contour quality assurance for HN005 clinical trial.</i> <b>Poster #:</b> 3735 <b>Presenter:</b> Du Wang, MS <b>Session Number:</b> PQA 09	<b>Location:</b> Hall F <b>Session:</b> Hematologic Malignancies, Digital Health Innovation and Informatics <b>Time:</b> 4:00pm - 5:00pm PT <b>POSTER</b>
Hematology	<b>Title:</b> <i>Consensus organ at risk (OAR) constraints for radiotherapy (RT) for hematologic malignancies for NCTN trials.</i> <b>Abstract #:</b> 1101 <b>Presenter:</b> Austin Sim, MD, JD <b>Session Number:</b> QP 17 - Hem 3	<b>Location:</b> Room 153 <b>Session:</b> Radiating Precision: Tailoring Therapy for Lymphoma, Leukemia, and Myeloma <b>Time:</b> 5:45pm - 5:50pm PT <b>Duration:</b> 5 minutes <b>Quick Pitch ORAL Presentation</b>
<b>Disease Site &amp; Study #</b>	<b>Wednesday, October 1, 2025</b>	<b>Time/Location</b>
Head and Neck  NRG RTOG 0522	<b>Title:</b> <i>Genetic signatures predicting toxicity and overall survival in head and neck squamous cell carcinoma (HNSCC) patients treated with radiation and cisplatin.</i> <b>Abstract #:</b> 1122 <b>Presenter:</b> Joanne Weidhaas, MD, PhD <b>Session Number:</b> QP 21	<b>Location:</b> Room 159 <b>Session:</b> Radiation and Cancer Biology 6: Precision Medicine & Resistance Mechanisms <b>Time:</b> 8:15am - 8:20am PT <b>Duration:</b> 5 minutes <b>Quick Pitch ORAL Presentation</b>
Prostate  NRG-GU009	<b>Title:</b> <i>Feasibility study of AI-Assisted radiation therapy contour QA for prostate cancer multi-center clinical trial.</i> <b>Abstract #:</b> 356 <b>Presenter:</b> Ledi Wang, MS <b>Session Number:</b> SS 44	<b>Location:</b> Room 152 <b>Session:</b> Radiation and Cancer Physics 8: Workflow and On-board Imaging <b>Time:</b> 8:50am - 9:00am PT <b>Duration:</b> 10 minutes <b>ORAL Presentation</b>
Prostate  NRG-RTOG 9202 NRG-RTOG 9413 NRG-RTOG 9902 NRG-RTOG 0126 NRG-RTOG 0521	<b>Title:</b> <i>Hallmark interferon-alpha response analysis in localized prostate cancer: analysis of the NRG Oncology/RTOG 9202, 9413, 9902, 0126, and 0521 clinical trials.</i> <b>Abstract #:</b> 359 <b>Presenter:</b> Adam Olson, MD <b>Session Number:</b> SS 45 - GU 10	<b>Location:</b> Room 154 <b>Session:</b> Biomarker Breakthroughs in Prostate Cancer <b>Time:</b> 10:50am - 11:00am PT <b>Duration:</b> 10 minutes <b>ORAL Presentation</b>

Disease Site & Study #	The following presentations include NRG author/investigators from NCTN sponsored federal trials, and NSABP-RTOG-GOG Foundation studies	Time/Location
Breast  RTOGF 3510 [RADCOMP]	<p><b>Title:</b> <i>Phase III randomized trial of proton vs. photon therapy for patients with non-metastatic breast cancer receiving comprehensive nodal radiation: a radiotherapy comparative effectiveness (RADCOMP) consortium trial: health-related quality of life outcomes.</i></p> <p><b>Session Number:</b> PL 01</p> <p><b>Presenter:</b> Shannon MacDonald, MD</p> <p><b>NRG Info:</b> RTOG Foundation Abstract</p>	<p><b>Monday, September 29, 2025</b></p> <p><b>Location:</b> San Francisco Ballroom</p> <p><b>Session:</b> Plenary</p> <p><b>Time:</b> 1:30-1:40pm PT</p> <p><b>Duration:</b> 10 minutes</p> <p><b>PLENARY</b></p>
Prostate  RTOGF 3506 [STEEL]	<p><b>Title:</b> <i>A randomized phase 2 study of enhanced AR blockade with enzalutamide in high-risk patients with biochemical relapse undergoing salvage radiation: final results from RTOG 3506 (STEEL).</i></p> <p><b>Session Number:</b> LBA 01</p> <p><b>Presenter:</b> Edwin Posadas, MD</p> <p><b>NRG Info:</b> RTOG Foundation Abstract</p>	<p><b>Tuesday, September 30, 2025</b></p> <p><b>Location:</b> Room 22/23</p> <p><b>Session:</b> Late Breaking Abstracts</p> <p><b>Time:</b> 2:40-2:50pm PT</p> <p><b>Duration:</b> 10 minutes</p> <p><b>ORAL Presentation</b></p>
Lung  NRG RTOG-0617	<p><b>Title:</b> <i>Independent external validation of radiation-induced esophagitis prediction during chemoradiation therapy for NSCLC using RTOG 0617 trial data.</i></p> <p><b>Abstract #:</b> 337</p> <p><b>Presenter:</b> Laura Cella, PhD</p> <p><b>Session Number:</b> TBDSS 41</p> <p><b>NRG Info:</b> Data Archive Project</p>	<p><b>Tuesday, September 30, 2025</b></p> <p><b>Location:</b> Room 20/21</p> <p><b>Session:</b> Radiation and Cancer Physics 7: AI-Driven Imaging and Predictive Modeling</p> <p><b>Time:</b> 3:00pm-3:10pm PT</p> <p><b>Duration:</b> 10 minutes</p> <p><b>ORAL Presentation</b></p>
Lung  NRG RTOG-0617	<p><b>Title:</b> <i>Impact of AI-based coronary artery calcium (CAC) scores and heart dose on survival in locally-advanced non-small-cell lung cancer (LA-NSCLC): a secondary analysis of RTOG 0617.</i></p> <p><b>Abstract #:</b> 348</p> <p><b>Presenter:</b> Nilanjan Haldar, MD</p> <p><b>Session Number:</b> SS 43</p> <p><b>NRG Info:</b> Data Archive Project</p>	<p><b>Tuesday, September 30, 2025</b></p> <p><b>Location:</b> Room 155/157</p> <p><b>Session:</b> Lung 5: Locally Advanced NSCLC: PORT and Cardiac Toxicity</p> <p><b>Time:</b> 4:20pm-4:30pm PT</p> <p><b>Duration:</b> 10 minutes</p> <p><b>ORAL Presentation</b></p>
Lung  NRG RTOG-0617	<p><b>Title:</b> <i>Prediction of radiation pneumonitis using dose and computed tomography data: first insights from the prospective RTOG 0617 and REQUITE Trials.</i></p> <p><b>Abstract #:</b> 3715</p> <p><b>Presenter:</b> Lukas Reuter, BS</p> <p><b>Session Number:</b> PQA 09</p> <p><b>NRG Info:</b> Data Archive Project</p>	<p><b>Tuesday, September 30, 2025</b></p> <p><b>Location:</b> TBD</p> <p><b>Session:</b> Hematologic Malignancies, Digital Health Innovation and Informatics</p> <p><b>Time:</b> 4:00pm-5:00pm PT</p> <p><b>POSTER</b></p>
Head & Neck  NRG-RTOG 9501 EORTC 22931	<p><b>Title:</b> <i>Re-examining post-operative chemoradiotherapy in head and neck cancer: an updated long-term combined analysis of RTOG 9501/EORTC 22931.</i></p> <p><b>Abstract #:</b> 313</p> <p><b>Presenter:</b> Zachary Zumsteg, MD</p> <p><b>Session Number:</b> SS 37 - Head and Neck 4</p> <p><b>NRG Info:</b> Data Sharing Project</p>	<p><b>Tuesday, September 30, 2025</b></p> <p><b>Location:</b> Room 314</p> <p><b>Session:</b> Refining Radiation: What Clinical Trials Can Tell Us</p> <p><b>Time:</b> 12:55pm – 1:05pm PT</p> <p><b>Duration:</b> 10 minutes</p> <p><b>ORAL Presentation</b></p>